- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02065271
Herbal Preparation and Glucose Homeostasis (Herbie)
Rationale: The incidence of obesity and type 2 diabetes (T2D) is increasing rapidly and accounts for a considerable part of health care costs. Herbal supplements are used in many cultures for the prevention and treatment of many different conditions. Due to lack of scientific proof, the application in western cultures are minimal. Animal studies have shown that many constituents of such herbal supplements may have beneficial effects on several important parameters known to be affected in T2D. Still, no scientific proof in humans is available. We therefore aim to investigate the effect of 4-week herbal supplementation on glucose metabolism, lipid metabolism, vascular function and inflammation in subjects with increased fasting glucose levels or a decreased glucose tolerance.
Objective: The primary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on blood glucose levels and glucose tolerance. The secondary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, inflammation, adipose tissue and white blood cell gene-expression and AIX both fasted and during an OGTT test.
Study design: This study is a randomized, double-blind, placebo controlled cross-over trial in which two different treatments will be evaluated e.g. an intervention with the herbal mixture and a placebo. Each person will obtain both treatments in random order for four weeks with a wash out period of four weeks in-between. Fasting blood samples will be collected and subjects will receive a OGTT, paralleled by a PWA before and after 4-week supplementation.
Furthermore, after 4-week supplement intake we will collect a urine sample and collect an adipose tissue biopsy. The whole trial will last three months.
Study population: 26 overweight males and females 50-75yrs old with an increased fasting glucose or with an impaired glucose tolerance.
Intervention: Two intervention periods of 4-weeks in which participants will take three times a day a supplement of 500mg herbal or placebo.
Main study parameters/endpoints: Fasting blood glucose levels, glucose tolerance as determined by an oral glucose tolerance test (OGTT), AIX, triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, PWA, adipose tissue an white blood cell gene expression and markers of inflammation .
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects that will participate in the study will invest a total of 16.5 hours. Blood collection by vena punctures/insertion of the venflon and the collection of an adipose tissue biopsy can occasionally cause a local hematoma or bruise and some participants may report pain or discomfort. The herbal supplements contain small amounts St. John's wort, which may affect the function of liver enzymes. We will therefore monitor liver function parameters during the supplementation period. Furthermore, subjects are excluded if they use medication known to be affected by St. John's wort. Participant will donate 284ml of blood, dispersed over 12 weeks.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Gelderland
-
Wageningen, Gelderland, Holanda, 6703 HD
- Wageningen University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Males and postmenopausal females For females: menstrual cycle absent for more than 1 year
- age 50-70yrs
- BMI >27 kg/m2
- Increased fasting glucose or an impaired glucose tolerance (two-hour glucose levels >7.8 mmol/L on the 75-g oral glucose tolerance test or fasting glucose >6.1mmol/L).
Exclusion Criteria:
- Systolic blood pressure >160mmHg and diastolic blood pressure> 100mmHg
- Tobacco smoker
- Received inoculations within 2 months of starting the study or planned during the study
- Donated or intend to donate blood from 2 months before the study till months after the study.
- Unstable body weight (weight gain or loss >5kg in the past three months)
- Diagnosed with any long-term medical condition (e.g., diabetes, haemophilia, CVD, anemia, gastrointestinal disease, renal failure, thyroid disorders, cancer, HIV, hepatitis C)
- The use of the following medicine: medicine interfering with St Johns Worth such as, inhibitors of the immune system (ciclosporine, tacrolimus, everolimus, temsirolimus and sirolimus), coumarine type anticoagulant medicine (acenocoumarol and fenprocoumon), anti-epileptica (fenobarbital and fenytoïne), theophylline, atorvastatine, simvastatine, digoxine, kinidine, voriconazol, proton pump inhibitors (omeprazole and esomeprazole) and all anti-depressives ( incl. MAO inhibitors and SSRI's).
- Abuse of drugs/alcohol
- If the participant don't want to sign the informed consent
- If the participant don't want to be informed about unexpected findings during the screening or study
- Participation in another biomedical study
- Additional exclusion criteria for females:
Current use of contraceptives containing hormones Current use of hormone replacement therapy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: herbal supplements
500mg, 3 per day, 4weeks
|
|
Comparador de Placebo: placebo
500mg, 3 per day, 4 weeks
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
change in glucose tolerance
Prazo: baseline and after 4-week supplementation
|
by oral glucose tolerance test (OGTT)
|
baseline and after 4-week supplementation
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
change in insulin
Prazo: baseline and after 4-week supplementation
|
baseline and after 4-week supplementation
|
|
change in TAG
Prazo: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
change in HbA1c
Prazo: baseline and after 4 week supplementation
|
glycosylated haemoglobin
|
baseline and after 4 week supplementation
|
change in FFA
Prazo: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
change in cholesterol
Prazo: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
change in vascular function
Prazo: baseline and after 4-week supplementation
|
by pulse wave analysis (PWA)
|
baseline and after 4-week supplementation
|
change in ALAT/ASAT
Prazo: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
Urinary metabolites
Prazo: after 4 week supplementation
|
after 4 week supplementation
|
|
adipose tissue gene expression
Prazo: after 4 week supplementation
|
by qpcr
|
after 4 week supplementation
|
change in markers of inflammation
Prazo: baseline and after 4 week of supplementation
|
by PBMC genexpression and plasma cytokines
|
baseline and after 4 week of supplementation
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Lydia A Afman, PhD, Wageningen University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NL44919.081.13
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em herbal supplement
-
Ohio State UniversityNatreon, Inc.Desconhecido
-
Alcon ResearchConcluídoVisãoEstados Unidos
-
Hamdard UniversityConcluído
-
University of Maryland, BaltimoreAlliance Institute for Integrative MedicineConcluídoEstado pré-diabéticoEstados Unidos
-
British Columbia Cancer AgencyNational Cancer Institute (NCI)ConcluídoCâncer de pulmão | Condição pré-cancerosa
-
Fundación VithasCEU San Pablo UniversityRecrutamentoNeoplasia/Câncer Relacionado à NutriçãoEspanha
-
European Institute of OncologyRecrutamentoNeoplasia NeuroendócrinaItália
-
Amphia HospitalRecrutamentoNeoplasias colônicas malignasHolanda
-
University of Roma La SapienzaAssociazione Italiana per la Ricerca sul CancroRecrutamentoCâncer de cólon estágio II | Câncer de cólon estágio IIIItália
-
Centre Hospitalier Universitaire de NiceRecrutamentoSangramentos retais isoladosFrança